Shots:
- Metsera has declared Novo Nordisk’s unsolicited ~$9B acquisition proposal, valuing shares up to $77.75, as a “Superior Company Proposal” than its existing Pfizer Merger Agreement
- The 2-step proposal incl. an initial $56.5/share cash payment & issuance of non-voting preferred stock for 50% of Metsera’s share capital, followed by a CVR of ~$21.25/share in cash based on milestones substantially similar to those in the proposed merger between Metsera & Pfizer, & Novo acquiring the remaining shares
- Metsera has notified Pfizer, triggering a 4-day negotiation window to adjust merger terms; the Pfizer agreement remains in effect, with no shareholder action required
Ref: Metsera | Image: Metsera | Press Release
Related News:- Pfizer Expands into Obesity Treatments with ~$7.3B Metsera Acquisition
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
